GlobalData on MSN7d
AbbVie and Xilio to collaborate on antibody-based immunotherapiesAbbVie has entered a partnership and option-to-license agreement with Xilio for tumour-activated, antibody-based ...
AbbVie Inc (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO) announced a collaboration and option-to-license agreement to ...
Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including ...
AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal
Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. | Having kicked off the year with ...
Feb. 12, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people ...
Investing.com -- Shares of Xilio Therapeutics Inc surged 175% on Wednesday in pre-market trading following the announcement ...
US pharma major AbbVie has announced a deal with Xilio Therapeutics, more than doubling the latter’s share price.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback